Lee's Pharmaceutical Holdings (SEHK:950) - Cotización, noticias y análisis

Resumen de acción 950

Lee's Pharmaceutical Holdings Limited, sociedad de cartera de inversiones, desarrolla, fabrica, comercializa y vende productos farmacéuticos principalmente en la República Popular China.

Acerca de la empresa

950 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 16.14%

Análisis de riesgos

Los beneficios han disminuido un 3.4% al año en los últimos 5 años

Grandes partidas extraordinarias que afectan a los resultados financieros

Los márgenes de beneficio (1.6%) son inferiores a los del año pasado (4.2%)

No tiene una capitalización de mercado significativa (HK$642M)

Competidores de Lee's Pharmaceutical Holdings Limited

JBM (Healthcare)

SEHK:2161

HK$728.3m

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$1.1b

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$1.0b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Lee's Pharmaceutical Holdings
Historical stock prices
Current Share Price	HK$1.08
52 Week High	HK$1.75
52 Week Low	HK$1.09
Beta	0.95
1 Month Change	-10.74%
3 Month Change	-25.52%
1 Year Change	-28.00%
3 Year Change	-77.50%
5 Year Change	-83.64%
Change since IPO	107.69%

Noticias y actualizaciones recientes

Recent updates

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Have Insiders Sold Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Recently?

Dec 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In Lee's Pharmaceutical Holdings Limited (HKG:950)

Dec 08

Is Lee's Pharmaceutical Holdings Limited's (HKG:950) Recent Price Movement Underpinned By Its Weak Fundamentals?

Dec 01

Is Lee's Pharmaceutical Holdings Limited (HKG:950) A Strong Dividend Stock?

Nov 18

Rentabilidad de los accionistas

	950	HK Pharmaceuticals	Mercado HK
7D	-6.9%	6.0%	3.5%
1Y	-28.0%	-16.8%	-9.9%

Rentabilidad vs. Industria: 950 obtuvo unos resultados inferiores a los del sector Hong Kong Pharmaceuticals , que el año pasado arrojó un rendimiento del -17.6%.

Rentabilidad vs. Mercado: 950 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fue del -10.1% el año pasado.

Volatilidad de los precios

Is 950's price volatile compared to industry and market?
950 volatility
950 Average Weekly Movement	5.4%
Pharmaceuticals Industry Average Movement	6.4%
Market Average Movement	7.4%
10% most volatile stocks in HK Market	14.7%
10% least volatile stocks in HK Market	3.6%

Precio estable de las acciones: El precio de las acciones de 950 ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 950 (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1994	1,057	n/a	www.leespharm.com

Lee's Pharmaceutical Holdings Limited, un holding de inversiones, desarrolla, fabrica, comercializa y vende productos farmacéuticos principalmente en la República Popular China. Sus actividades se centran en diversas enfermedades, como las cardiovasculares, la salud de la mujer, la pediatría, las enfermedades raras, la oncología, la dermatología y la obstetricia. Opera a través de los segmentos de Productos Patentados y Genéricos, y Productos Bajo Licencia.

Resumen de fundamentos de Lee's Pharmaceutical Holdings Limited

¿Cómo se comparan los beneficios e ingresos de Lee's Pharmaceutical Holdings con su capitalización de mercado?
Estadísticas fundamentales de 950
Capitalización bursátil	HK$641.83m
Beneficios(TTM)	HK$16.70m
Ingresos (TTM)	HK$1.05b

38.1x

Ratio precio-beneficio (PE)

0.6x

Ratio precio-ventas (PS)

¿Está 950 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 950
Ingresos	HK$1.05b
Coste de los ingresos	HK$501.72m
Beneficio bruto	HK$551.31m
Otros gastos	HK$534.61m
Beneficios	HK$16.70m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.028
Margen bruto	52.35%
Margen de beneficio neto	1.59%
Ratio deuda/patrimonio	9.8%

¿Cómo se ha desempeñado 950 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.7%

Rentabilidad actual por dividendo

63%

Ratio de pagos

¿Paga 950 dividendos fiables?

Ver historial de dividendos e índices de referencia de 950

¿Cuándo hay que comprar 950 para recibir un próximo dividendo?
fechas de dividendos de Lee's Pharmaceutical Holdings
Fecha ex dividendo	May 28 2024
Fecha de pago de dividendos	Jun 17 2024
Días hasta ex dividendo	31 days
Días hasta la fecha de pago de dividendos	51 days

¿Paga 950 dividendos fiables?

Ver historial de dividendos e índices de referencia de 950

Resumen de acción 950

Recompensas

Análisis de riesgos

Competidores de Lee's Pharmaceutical Holdings Limited

SEHK:2161

HK$728.3m

SEHK:503

HK$750.6m

SEHK:3737

HK$1.1b

SEHK:8049

HK$1.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Recent updates

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022

Price target decreased to HK$4.85

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020)

Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Price target decreased to HK$5.30

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation

Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020)